COMMUNIQUÉS West-GlobeNewswire

Altimmune to Participate in Two Upcoming Investor Conferences
23/09/2025
GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, [...]
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
23/09/2025
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for [...]
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
23/09/2025
Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable [...]
Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22
23/09/2025
Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22 First disclosure of a novel mechanism of action for the degradation of [...]
Microbix Assisting EMQN with Second Genetic-Test EQA Program
23/09/2025
Helping Ensure Appropriate Dosing of Widely-Used Anti-Clotting Drugs MISSISSAUGA, Ontario and MANCHESTER, United Kingdom, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix [...]
Transpire Bio’s ANDA for Generic Breo® Ellipta® Accepted for Filing By the U.S. FDA
23/09/2025
SUNRISE, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces [...]
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
23/09/2025
FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized as [...]
SEED Therapeutics Completes $30 Million Series A-3 Financing
23/09/2025
KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers [...]
Tilray Beverages Unveils New Fall Seasonal Craft Brews with Oktoberfest-Inspired Lineup
23/09/2025
ATLANTA, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global lifestyle and consumer packaged goods company, is raising a stein to the season with a festive lineup of [...]
BPGbio Welcomes Back NAi Interrogative Biology® Platform Co-Inventor Slava Akmaev, Ph.D., as Chief Operating Officer and Chief AI Officer
23/09/2025
Seasoned AI-Biotech veteran strengthens the company’s leadership in AI and mitochondrial medicine Co-Inventor of AI platform boosts company’s momentum in advancing late-stage assets to commercialization BOSTON, Sept. 23 [...]
BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
23/09/2025
MAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host its second AI Day, an edition [...]
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announced the Closing of Their Previously Announced Business Combination on September 22, 2025
23/09/2025
Semnur’s shares of common stock and warrants are expected to trade on the OTC Markets on September 23, 2025 under the ticker symbols “SMNR” and “SMNRW”, respectively. Scilex (together with its affiliates) owns [...]
NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor
23/09/2025
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc. , an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, [...]
Labviva Kicks Off Smart Lab of the Future Tour
23/09/2025
Life sciences procurement leader showcases AI-driven supply chain innovation at global events BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Labviva , the leading AI-powered procurement platform for life sciences, today [...]
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
23/09/2025
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00 CEST / 13:00 BST / 08:00 EDT. Details are at the end of this news release Pratteln, Switzerland, September 23, [...]
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
23/09/2025
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 23, 2025, at 14:00 CEST / 13:00 BST / 08:00 BST. Details are at the end of this news release Pratteln, Switzerland, September 23, [...]
Addex Appoints Bank of New York Mellon as Depositary Bank
23/09/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
23/09/2025
Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK expression Myotonic [...]
Communiqué de presse : La thérapie SAR446268 de Sanofi obtient son admission dans la procédure accélérée américaine pour le traitement de la dystrophie myotonique non congénitale de type 1
23/09/2025
La thérapie SAR446268 de Sanofi obtient son admission dans la procédure accélérée américaine pour le traitement de la dystrophie myotonique non congénitale de type 1 Admission obtenue pour la thérapie génique AAV unique [...]

Pages